Hydrochloric Acid

SCHEMBL691540

CC(C)(CCCC(N)=O)C(N)=O.Cl.Cl

nearest known ligand 0.35

Known targets — ChEMBL curated mechanism

ABL1 ACE ACHE ACVR1 ADRA1A ADRA1B ADRA1D ADRA2A ADRA2B ADRA2C ADRB1 ADRB2 ADRB3 AGTR1 ALK AVPR1A AVPR2 BCHE BCR CA2 CACNA1A CACNA1B CACNA1C CACNA1D CACNA1E CACNA1F CACNA1G CACNA1H CACNA1I CACNA1S CACNA2D1 CACNA2D2 CACNA2D3 CACNA2D4 CACNB1 CACNB2 CACNB3 CACNB4 CACNG1 CACNG2 CACNG3 CACNG4 CACNG5 CACNG6 CACNG7 CACNG8 CALCRL CASR CCR5 CDK4 CDK6 CFB CHRM1 CHRM2 CHRM3 CHRM4 CHRM5 CHRNA1 CHRNA3 CHRNA7 CHRNB1 CHRNB4 CHRND CHRNE CHRNG COXFA4 COXFA4L2 CRBN CSF1R CUL4A CYP19A1 DDB1 DPP4 DRD1 DRD2 DRD3 DRD4 EDNRA EGFR EML4 ERBB2 ERBB4 ESR1 ESR2 FGFR1 FGFR3 FLT1 FLT3 FLT4 GAA GABRA1 GABRA2 GABRA3 GABRA4 GABRA5 GABRA6 GABRB1 GABRB2 GABRB3 GABRD GABRE GABRG1 GABRG2 GABRG3 GABRP GABRQ GHSR GLA GNRHR GPD2 GRIN1 GRIN2A GRIN2B GRIN2C GRIN2D GRIN3A GRIN3B GSTP1 HCN4 HCRTR1 HCRTR2 HDAC1 HDAC10 HDAC11 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HRH1 HRH2 HRH3 HSD11B1 HSP90AA1 HSP90AB1 HTR1A HTR1B HTR1D HTR1E HTR1F HTR2A HTR2B HTR2C HTR3A HTR3B HTR3C HTR3D HTR3E HTR4 HTR5A HTR6 HTR7 IMPDH1 IMPDH2 ITGA2B ITGB3 ITK JAK1 JAK2 KCNA1 KCNA10 KCNA2 KCNA3 KCNA4 KCNA5 KCNA6 KCNA7 KCNB1 KCNB2 KCNC1 KCNC2 KCNC3 KCNC4 KCND1 KCND2 KCND3 KCNF1 KCNG1 KCNG2 KCNG3 KCNG4 KCNH1 KCNH2 KCNH3 KCNH4 KCNH5 KCNH6 KCNH7 KCNH8 KCNJ2 KCNJ3 KCNJ5 KCNK3 KCNK9 KCNQ1 KCNQ2 KCNQ3 KCNQ4 KCNQ5 KCNS1 KCNS2 KCNS3 KCNV1 KCNV2 KDR KIT KLKB1 LCK M MAOA MAOB MAPK14 MET MMP1 MMP13 MMP7 MMP8 MT-ND1 MT-ND2 MT-ND3 MT-ND4 MT-ND4L MT-ND5 MT-ND6 NDUFA1 NDUFA10 NDUFA11 NDUFA12 NDUFA13 NDUFA2 NDUFA3 NDUFA5 NDUFA6 NDUFA7 NDUFA8 NDUFA9 NDUFAB1 NDUFAF1 NDUFAF2 NDUFAF3 NDUFAF4 NDUFB1 NDUFB10 NDUFB11 NDUFB2 NDUFB3 NDUFB4 NDUFB5 NDUFB6 NDUFB7 NDUFB8 NDUFB9 NDUFC1 NDUFC2 NDUFS1 NDUFS2 NDUFS3 NDUFS4 NDUFS5 NDUFS6 NDUFS7 NDUFS8 NDUFV1 NDUFV2 NDUFV3 NR3C1 NS5A NTRK1 NTRK2 NTRK3 ODC1 OPRD1 OPRK1 OPRM1 P2RY12 PAH PARP1 PDE3A PDE3B PDE4A PDE4B PDE4C PDE4D PDE5A PDE7A PDE7B PDE8A PDE8B PDGFRA PDGFRB PIK3CA PIK3CD PNP POLA1 POLA2 POLD1 POLD2 POLD3 POLD4 POLE POLE2 POLE3 PPARG PRIM1 PRIM2 PRKCA PRKCB PRKCD PRKCE PRKCG PRKCH PRKCI PRKCQ PRKCZ PRKD1 PRKD3 PTGS1 PTGS2 RBX1 REN RET ROCK1 ROCK2 RPE65 RRM1 RRM2 RRM2B S1PR1 S1PR2 S1PR3 S1PR4 S1PR5 SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SCNN1A SCNN1B SCNN1G SIGMAR1 SLC18A2 SLC6A1 SLC6A2 SLC6A3 SLC6A4 SLC9A3 SRC TACR1 TOP1 TOP2A TOP2B TTR TYMP dacA dacB dacC embA folA ftsI gyrA gyrB mrcA mrcB mrdA parC parE pol rplA rplB rplC rplD rplE rplF rplI rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmE2 rpmF rpmG rpmG1 rpmG2 rpmG3 rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	GLA known ✓	P06280	1/20	0.35

▸	KDM4E	B2RXH2	4/20	0.35

▸	TP53	P04637	2/20	0.35

▸	CYP1A2	P05177	2/20	0.35

▸	CYP3A4	P08684	2/20	0.35

▸	CYP2C19	P33261	2/20	0.35

▸	ALDH1A1	P00352	2/20	0.35

▸	LMNA	P02545	2/20	0.35

▸	HSD17B10	Q99714	2/20	0.35

▸	ALOX15	P16050	2/20	0.35

▸	BLM	P54132	2/20	0.35

▸	PMP22	Q01453	2/20	0.35

▸	TDP1	Q9NUW8	2/20	0.35

▸	GMNN	O75496	1/20	0.35

▸	USP2	O75604	1/20	0.35

▸	POLB	P06746	1/20	0.35

▸	CYP2C9	P11712	1/20	0.35

▸	HPGD	P15428	1/20	0.35

▸	THPO	P40225	1/20	0.35

▸	RECQL	P46063	1/20	0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Hydrochloric Acid SCHEMBL561987	1.00	KDM4E (0.35)	KDM4ETP53CYP1A2CYP3A4CYP2C19
SCHEMBL232206	0.97	KDM4E (0.36)	KDM4ETP53CYP1A2CYP3A4CYP2C19
Hydrochloric Acid SCHEMBL515770	0.93	SOAT1 (0.38)	KDM4ETP53CYP1A2CYP3A4CYP2C19
Hydrochloric Acid SCHEMBL562372	0.93	SOAT1 (0.38)	KDM4ETP53CYP1A2CYP3A4CYP2C19
Hydrochloric Acid SCHEMBL316931	0.91	SOAT1 (0.41)	KDM4ETP53CYP1A2CYP3A4CYP2C19
Hydrochloric Acid SCHEMBL561964	0.91	SOAT1 (0.41)	KDM4ETP53CYP1A2CYP3A4CYP2C19
SCHEMBL154713	0.90	SOAT1 (0.39)	KDM4ETP53CYP1A2CYP3A4CYP2C19
SCHEMBL250912	0.88	SOAT1 (0.42)	KDM4ETP53CYP1A2CYP3A4CYP2C19
SCHEMBL4151443	0.88	SOAT1 (0.42)	KDM4ETP53CYP1A2CYP3A4CYP2C19
Hydrochloric Acid SCHEMBL6214815	0.87	LMNA (0.36)	KDM4ETP53CYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
WO-2010063725-A2	STRUCTURING PARTICLES INTO USEFUL STRUCTURES AND THEIR USE IN LIFE SCIENCE	MATTIASSON BO (SE)	2010-06-10	—	—	WO	claimed
US-7538092-B2	Pharmaceutically active oligosaccharide conjugates	FRESENIUS KABI DEUTSCHLAND GMBH (DE)	2009-05-26	—	—	US	claimed
EP-1549350-B1	PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES	FRESENIUS KABI DE GMBH (DE)	2008-09-24	—	—	EP	claimed
US-20080090918-A1	Separation medium, its preparation and its use	PROTISTA BIOTECHNOLOGY AB (SE)	2008-04-17	—	—	US	claimed
US-20070054364-A1	Polypeptide variants	ASTERION LIMITED (GB)	2007-03-08	—	—	US	claimed
US-20060100163-A1	Pharmaceutically active oligosaccharide conjugates	FRESENIUS KABI DEUTSCHLAND GMBH (DE)	2006-05-11	—	—	US	claimed
US-20050214762-A1	Polypeptide variants	ASTERION LIMITED (GB)	2005-09-29	—	—	US	claimed
US-20050029191-A1	Macroporous gel; cooling aqueous solution of gel forming polymer and solvent at a temperature which freezes solvent	PROTISTA BIOTECHNOLOGY AB (SE)	2005-02-10	—	—	US	claimed
EP-1468020-A2	MULTIMERS OF RECEPTOR-BINDING LIGANDS	Asterion Limited (GB)	2004-10-20	—	—	EP	claimed
US-20040147437-A1	Calycins	LEEDS, THE UNIVERSITY OF (GB)	2004-07-29	—	—	US	claimed
EP-1436058-A1	SEPARATION MEDIUM, ITS PREPARATION AND ITS USE	Protista International AB (SE)	2004-07-14	—	—	EP	claimed
US-20030148304-A1	Method for immobilisation	KAROLINSKA INNOVATIONS AB (SE)	2003-08-07	—	—	US	claimed
WO-2003062276-A2	MULTIMERS OF RECEPTOR-BINDING LIGANDS	ASTERION LIMITED (GB)	2003-07-31	—	—	WO	claimed
EP-1315522-A2	CALYCINS	THE UNIVERSITY OF LEEDS (GB)	2003-06-04	—	—	EP	claimed
WO-2003031014-A1	SEPARATION MEDIUM, ITS PREPARATION AND ITS USE	PROTISTA INTERNATIONAL AB (SE)	2003-04-17	—	—	WO	claimed
EP-1235937-A1	METHOD FOR IMMOBILISATION	Karolinska Innovations AB (SE)	2002-09-04	—	—	EP	claimed
WO-2002015939-A2	CALYCINS	UNIVERSITY OF LEEDS (GB)	2002-02-28	—	—	WO	claimed
WO-2001042501-A1	METHOD FOR IMMOBILISATION	KAROLINSKA INNOVATIONS AB (SE)	2001-06-14	—	—	WO	claimed
EP-0248621-B1	REAGENT FOR IMMUNOASSAY	KABUSHIKI KAISHA TOSHIBA (JP)	1992-08-26	—	—	EP	claimed
US-20230338614-A1	Silk-Hyaluronic Acid Based Tissue Filers and Methods of Using the Same	EVOLVED BY NATURE, INC.	2023-10-26	—	—	US	disclosed
US-20230190997-A1	SILK-HYALURONIC ACID BASED TISSUE FILERS AND METHODS OF USING THE SAME	EVOLVED BY NATURE INC (US)	2023-06-22	—	—	US	disclosed
US-11660372-B2	Silk-hyaluronic acid based tissue fillers and methods of using the same	EVOLVED BY NATURE, INC. (US)	2023-05-30	—	—	US	disclosed
EP-4167949-A1	SILK-HYALURONIC ACID COMPOSITIONS FOR TISSUE FILLING, TISSUE SPACING, AND TISSUE BULKING	Evolved by Nature, Inc. (US)	2023-04-26	—	—	EP	disclosed
EP-4169539-A1	SILK-HYALURONIC ACID BASED TISSUE FILLERS AND METHODS OF USING THE SAME	Evolved by Nature, Inc. (US)	2023-04-26	—	—	EP	disclosed
US-20230114250-A1	SILK-HYALURONIC ACID TISSUE FILLERS AND METHODS OF MAKING AND USING THE SAME	EVOLVED BY NATURE, INC.	2023-04-13	—	—	US	disclosed
CN-114929743-A	anti-STEAP 1 antibodies and uses thereof	纪念斯隆凯特琳癌症中心	2022-08-19	—	—	CN	disclosed
US-20220193304-A1	SILK-HYALURONIC ACID BASED TISSUE FILLERS AND METHODS OF USING THE SAME	EVOLVED BY NATURE, INC.	2022-06-23	—	—	US	disclosed
CN-114502584-A	CD33 antibodies and methods of using the same for treating cancer	纪念斯隆凯特琳癌症中心	2022-05-13	—	—	CN	disclosed
CN-114341176-A	CD19 antibodies and methods of use thereof	纪念斯隆凯特琳癌症中心	2022-04-12	—	—	CN	disclosed
CN-114341182-A	DLL3 targeting antibodies and uses thereof	纪念斯隆凯特琳癌症中心	2022-04-12	—	—	CN	disclosed
WO-2021258030-A1	SILK-HYALURONIC ACID COMPOSITIONS FOR TISSUE FILLING, TISSUE SPACING, AND TISSUE BULKING	EVOLVED BY NATURE, INC. (US)	2021-12-23	—	—	WO	disclosed
EP-3897564-A1	SILK-HYALURONIC ACID TISSUE FILLERS AND METHODS OF MAKING AND USING THE SAME	Evolved by Nature, Inc. (US)	2021-10-27	—	—	EP	disclosed
CN-112566642-A	Anti-polysialic acid antibody and use thereof	纪念斯隆凯特琳癌症中心	2021-03-26	—	—	CN	disclosed
US-20200376159-A1	CO-CROSSLINKED HYALURONIC ACID-SILK FIBROIN HYDROGELS FOR IMPROVING TISSUE GRAFT VIABILITY AND FOR SOFT TISSUE AUGMENTATION	ALLERGAN, INC.	2020-12-03	—	—	US	disclosed
US-20200352843-A1	CROSS LINKED SILK-HYALURONIC ACID COMPOSITION	ALLERGAN, INC.	2020-11-12	—	—	US	disclosed
US-10758470-B2	Cross linked silk-hyaluronic acid composition	ALLERGAN, INC. (US)	2020-09-01	—	—	US	disclosed
US-10744227-B2	Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation	ALLERGAN, INC. (US)	2020-08-18	—	—	US	disclosed
EP-2421551-B2	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN INC (US)	2020-07-15	—	—	EP	disclosed
CN-111372590-A	A33 antibody compositions and methods of using the same in radioimmunotherapy	纪念斯隆-凯特林癌症中心	2020-07-03	—	—	CN	disclosed
WO-2020132331-A1	SILK-HYALURONIC ACID TISSUE FILLERS AND METHODS OF MAKING AND USING THE SAME	EVOLVED BY NATURE, INC. (US)	2020-06-25	—	—	WO	disclosed
EP-3645063-A1	SILK-HYALURONIC ACID BASED TISSUE FILLERS AND METHODS OF USING THE SAME	Evolved by Nature, Inc. (US)	2020-05-06	—	—	EP	disclosed
CN-111093693-A	anti-L1-CAM antibodies and uses thereof	纪念斯隆-凯特林癌症中心	2020-05-01	—	—	CN	disclosed
US-20190255215-A1	CO-CROSSLINKED HYALURONIC ACID-SILK FIBROIN HYDROGELS FOR IMPROVING TISSUE GRAFT VIABILITY AND FOR SOFT TISSUE AUGMENTATION	ALLERGAN, INC.	2019-08-22	—	—	US	disclosed
EP-3503841-A1	CO-CROSSLINKED HYALURONIC ACID-SILK FIBROIN HYDROGELS FOR IMPROVING TISSUE GRAFT VIABILITY AND FOR SOFT TISSUE AUGMENTATION	Allergan, Inc. (US)	2019-07-03	—	—	EP	disclosed
EP-2988791-B1	CROSS LINKED SILK-HYALURONIC ACID COMPOSITION	ALLERGAN INC (US)	2019-06-12	—	—	EP	disclosed
US-10300169-B2	Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation	ALLERGAN, INC. (US)	2019-05-28	—	—	US	disclosed
CN-106030310-B	Soluble high-molecular amount (HMW) TAU type and its application	通用医疗公司	2019-01-04	—	—	CN	disclosed
WO-2019005848-A1	SILK-HYALURONIC ACID BASED TISSUE FILLERS AND METHODS OF USING THE SAME	Silk, Inc. (US)	2019-01-03	—	—	WO	disclosed
US-10154951-B2	Cross linked silk-hyaluronic acid composition	ALLERGAN, INC. (US)	2018-12-18	—	—	US	disclosed
US-20180303742-A1	CROSS LINKED SILK-HYALURONIC ACID COMPOSITION	ALLERGAN, INC.	2018-10-25	—	—	US	disclosed
US-20180055971-A1	CO-CROSSLINKED HYALURONIC ACID-SILK FIBROIN HYDROGELS FOR IMPROVING TISSUE GRAFT VIABILITY AND FOR SOFT TISSUE AUGMENTATION	ALLERGAN, INC.	2018-03-01	—	—	US	disclosed
WO-2018039496-A1	CO-CROSSLINKED HYALURONIC ACID-SILK FIBROIN HYDROGELS FOR IMPROVING TISSUE GRAFT VIABILITY AND FOR SOFT TISSUE AUGMENTATION	ALLERGAN, INC. (US)	2018-03-01	—	—	WO	disclosed
US-20160361247-A1	CROSS LINKED SILK-HYALURONIC ACID COMPOSITION	ALLERGAN, INC.	2016-12-15	—	—	US	disclosed
US-20160095695-A1	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC.	2016-04-07	—	—	US	disclosed
EP-2988791-A1	CROSS LINKED SILK-HYALURONIC ACID COMPOSITION	ALLERGAN, INC. (US)	2016-03-02	—	—	EP	disclosed
US-9150668-B2	Silk fibroin hydrogels and uses thereof	ALLERGAN, INC. (US)	2015-10-06	—	—	US	disclosed
US-9005606-B2	Silk fibroin hydrogels and uses thereof	ALLERGAN, INC. (US)	2015-04-14	—	—	US	disclosed
WO-2014176158-A1	CROSS LINKED SILK-HYALURONIC ACID COMPOSITION	ALLERGAN, INC. (US)	2014-10-30	—	—	WO	disclosed
US-20140315828-A1	CROSS-LINKED SILK-HYALURONIC ACID COMPOSITIONS	ALLERGAN, INC. (US)	2014-10-23	—	—	US	disclosed
US-20140206839-A1	CROSS LINKED HYALURONIC ACID-SILK AND USES THEREOF	ALLERGAN, INC. (US)	2014-07-24	—	—	US	disclosed
US-20140194987-A1	SILK COVERED BREAST IMPLANT	ALLERGAN, INC. (US)	2014-07-10	—	—	US	disclosed
EP-2421551-B1	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN INC (US)	2013-10-30	—	—	EP	disclosed
US-20130172995-A1	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC. (US)	2013-07-04	—	—	US	disclosed
EP-2421549-B1	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN INC (US)	2013-06-12	—	—	EP	disclosed
EP-2421550-B1	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN INC (US)	2013-06-12	—	—	EP	disclosed
US-8420077-B2	Silk fibroin hydrogels and uses thereof	ALLERGAN, INC. (US)	2013-04-16	—	—	US	disclosed
US-20120265297-A1	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC. (US)	2012-10-18	—	—	US	disclosed
US-8288347-B2	Dermal fillers comprising silk fibroin hydrogels and uses thereof	ALLERGAN, INC. (US)	2012-10-16	—	—	US	disclosed
US-20120172317-A1	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC. (US)	2012-07-05	—	—	US	disclosed
US-20120172985-A1	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC. (US)	2012-07-05	—	—	US	disclosed
US-20120171265-A1	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC. (US)	2012-07-05	—	—	US	disclosed
EP-2421549-A2	SILK FIBROIN HYDROGELS AND USES THEREOF	Allergan, Inc. (US)	2012-02-29	—	—	EP	disclosed
EP-2421551-A2	SILK FIBROIN HYDROGELS AND USES THEREOF	Allergan, Inc. (US)	2012-02-29	—	—	EP	disclosed
EP-2421550-A2	SILK FIBROIN HYDROGELS AND USES THEREOF	Allergan, Inc. (US)	2012-02-29	—	—	EP	disclosed
US-20110189292-A1	DERMAL FILLERS COMPRISING SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC. (US)	2011-08-04	—	—	US	disclosed
WO-2010123945-A9	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC. (US)	2011-06-03	—	—	WO	disclosed
US-20110129531-A1	Dermal Fillers Comprising Silk Fibroin Hydrogels and Uses Thereof	ALLERGAN, INC. (US)	2011-06-02	—	—	US	disclosed
US-20110111031-A1	Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof	ALLERGAN, INC.	2011-05-12	—	—	US	disclosed
US-20110052695-A1	DRUG DELIVERY PLATFORMS COMPRISING SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC. (US)	2011-03-03	—	—	US	disclosed
US-20110020409-A1	Silk Fibroin Hydrogels and Uses Thereof	ALLERGAN, INC.	2011-01-27	—	—	US	disclosed
US-20110014287-A1	Silk Fibroin Hydrogels and Uses Thereof	ALLERGAN, INC.	2011-01-20	—	—	US	disclosed
US-20110014263-A1	Silk Fibroin Hydrogels and Uses Thereof	ALLERGAN, INC.	2011-01-20	—	—	US	disclosed
US-20110008436-A1	Silk Fibroin Hydrogels and Uses Thereof	ALLERGAN, INC.	2011-01-13	—	—	US	disclosed
US-20110008437-A1	Silk Fibroin Hydrogels and Uses Thereof	ALLERGAN, INC.	2011-01-13	—	—	US	disclosed
US-20110008406-A1	Silk Fibroin Hydrogels and Uses Thereof	ALLERGAN, INC.	2011-01-13	—	—	US	disclosed
WO-2010123947-A2	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC. (US)	2010-10-28	—	—	WO	disclosed
WO-2010123946-A2	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC. (US)	2010-10-28	—	—	WO	disclosed
WO-2010123945-A2	SILK FIBROIN HYDROGELS AND USES THEREOF	ALLERGAN, INC. (US)	2010-10-28	—	—	WO	disclosed
WO-2010063725-A2	STRUCTURING PARTICLES INTO USEFUL STRUCTURES AND THEIR USE IN LIFE SCIENCE	MATTIASSON BO (SE)	2010-06-10	—	—	WO	disclosed
US-20100029568-A1	TIGHTER-BINDING C-PEPTIDE INHIBITORS OF HIV-1 ENTRY	THOMAS JEFFERSON UNIVERSITY (US)	2010-02-04	—	—	US	disclosed
EP-2125876-A1	TIGHTER-BINDING C-PEPTIDE INHIBITORS OF HIV-1 ENTRY	THOMAS JEFFERSON UNIVERSITY (US)	2009-12-02	—	—	EP	disclosed
EP-1608449-B1	CHROMATOGRAPHIC SEPARATION OF SUBSTANCES CONTAINED IN A LIQUID SAMPLE	PROTISTA BIOTECHNOLOGY AB (SE)	2009-02-18	—	—	EP	disclosed
WO-2008112736-A1	TIGHTER-BINDING C-PEPTIDE INHIBITORS OF HIV-1 ENTRY	THOMAS JEFFERSON UNIVERSITY (US)	2008-09-18	—	—	WO	disclosed
CN-101223169-A	Pyrrolo [2, 3-b ] pyridine derivative protein kinase inhibitors	PLEXXIKON INC (US)	2008-07-16	—	—	CN	disclosed
US-20080090918-A1	Separation medium, its preparation and its use	PROTISTA BIOTECHNOLOGY AB (SE)	2008-04-17	—	—	US	disclosed
EP-1642136-A4	METHOD OF ISOLATING A PROTEIN	PROTEOME SYSTEMS INTELLECTUAL (AU)	2007-12-12	—	—	EP	disclosed
US-20070163960-A1	Chromatographic separation method, separation device and process for the preparation of a separation medium for use therein	PROTISTA BIOTECHNOLOGY AB (SE)	2007-07-19	—	—	US	disclosed
US-20070054364-A1	Polypeptide variants	ASTERION LIMITED (GB)	2007-03-08	—	—	US	disclosed
EP-1206288-B1	TARGETED FIBERLESS RADIATIVE EFFECTORS	UNIV MICHIGAN (US)	2007-01-10	—	—	EP	disclosed
US-20060105942-A1	Inhibition of cell division based use of analogs of neuropeptide y	BIOACTA LIMITED (GB)	2006-05-18	—	—	US	disclosed
EP-1642136-A1	METHOD OF ISOLATING A PROTEIN	Proteome Systems Intellectual Property Pty Ltd. (AU)	2006-04-05	—	—	EP	disclosed
US-20050214762-A1	Polypeptide variants	ASTERION LIMITED (GB)	2005-09-29	—	—	US	disclosed
US-20050118598-A1	Organic compounds	GARCIA-ECHEVERRIA CARLOS (CH)	2005-06-02	—	—	US	disclosed
EP-1523501-A1	INHIBITION OF CELL DIVISION BASED USE OF ANALOGS OF NEUROPEPTIDE Y	Bioacta limited (GB)	2005-04-20	—	—	EP	disclosed
US-20050029191-A1	Macroporous gel; cooling aqueous solution of gel forming polymer and solvent at a temperature which freezes solvent	PROTISTA BIOTECHNOLOGY AB (SE)	2005-02-10	—	—	US	disclosed
WO-2005001480-A1	METHOD OF ISOLATING A PROTEIN	PROTEOME SYSTEMS INTELLECTUAL PROPERTY PTY LTD (AU)	2005-01-06	—	—	WO	disclosed
EP-1478665-A2	ORGANIC COMPOUNDS HAVING ANTI-ANGIOGENIC ACTIVITY	Novartis AG (CH)	2004-11-24	—	—	EP	disclosed
EP-1468020-A2	MULTIMERS OF RECEPTOR-BINDING LIGANDS	Asterion Limited (GB)	2004-10-20	—	—	EP	disclosed
WO-2004009110-A1	PEPTIDE M AS APOPTOSIS INDUCING AGENT	BIOACTA LIMITED (GB)	2004-01-29	—	—	WO	disclosed
WO-2004009628-A1	INHIBITION OF CELL DIVISION BASED USE OF ANALOGS OF NEUROPEPTIDE Y	BIOACTA LIMITED (GB)	2004-01-29	—	—	WO	disclosed
WO-2004009128-A1	ANTI-ANGIOGENIC PEPTIDES	BIOACTA LIMITED (GB)	2004-01-29	—	—	WO	disclosed
WO-2003070769-A2	ORGANIC COMPOUNDS HAVING ANTI-ANGIOGENIC ACTIVITY	NOVARTIS AG (CH)	2003-08-28	—	—	WO	disclosed
US-20030148304-A1	Method for immobilisation	KAROLINSKA INNOVATIONS AB (SE)	2003-08-07	—	—	US	disclosed
WO-2003062276-A2	MULTIMERS OF RECEPTOR-BINDING LIGANDS	ASTERION LIMITED (GB)	2003-07-31	—	—	WO	disclosed
EP-1235937-A1	METHOD FOR IMMOBILISATION	Karolinska Innovations AB (SE)	2002-09-04	—	—	EP	disclosed
EP-1206288-A2	TARGETED FIBERLESS RADIATIVE EFFECTORS	THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US)	2002-05-22	—	—	EP	disclosed
WO-2001042501-A1	METHOD FOR IMMOBILISATION	KAROLINSKA INNOVATIONS AB (SE)	2001-06-14	—	—	WO	disclosed
WO-2001008660-A2	TARGETED FIBERLESS RADIATIVE EFFECTORS	THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US)	2001-02-08	—	—	WO	disclosed
US-6022951-A	MODIFIED ANTIBIOTIC PEPTIDE FOR INCREASED OR DECREASED SENSITIVITY TO BIOTIN, AND METHODS FOR UTILIZING THESE PROTEINS IN DETECTION, ISOLATION AND PURIFICATION TECHNIQUES	U.S. DEPARTMENT OF ENERGY	2000-02-08	—	—	US	disclosed
EP-0856055-A1	STREPTAVIDIN MUTANTS	TRUSTEES OF BOSTON UNIVERSITY (US)	1998-08-05	—	—	EP	disclosed
EP-0578728-B1	PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIIIa	GENENTECH INC (US)	1998-07-01	—	—	EP	disclosed
US-5756452-A	CYCLIC POLYPEPTIDE	GENENTECH, INC. (US)	1998-05-26	—	—	US	disclosed
WO-1997011183-A1	STREPTAVIDIN MUTANTS	TRUSTEES OF BOSTON UNIVERSITY (US)	1997-03-27	—	—	WO	disclosed
US-5493007-A	OLIGOPEPTIDE	GENENTECH, INC. (US)	1996-02-20	—	—	US	disclosed
EP-0345723-B1	Diethylenetriamine pentaacetic acid derivatives	NIHON MEDIPHYSICS CO LTD (JP)	1994-05-25	—	—	EP	disclosed
EP-0578728-A1	PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIIIa	GENENTECH, INC. (US)	1994-01-19	—	—	EP	disclosed
US-5250702-A	Nonradioactive carriers for radioactive metal elements	NIHON MEDI-PHYSICS CO., LTD. (JP)	1993-10-05	—	—	US	disclosed
EP-0555328-A1	PLATELET AGGREGATION INHIBITORS	GENENTECH, INC. (US)	1993-08-18	—	—	EP	disclosed
WO-1992017492-A1	PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIII¿a?	GENENTECH, INC. (US)	1992-10-15	—	—	WO	disclosed
EP-0493506-A1	CHIMERIC AMINO ACIDS AND PEPTIDES CONTAINING THESE ANALOGUES	GENENTECH, INC. (US)	1992-07-08	—	—	EP	disclosed
US-5120859-A	Anticoagulants	GENENTECH, INC. (US)	1992-06-09	—	—	US	disclosed
WO-1992007870-A1	PLATELET AGGREGATION INHIBITORS	GENENTECH, INC. (US)	1992-05-14	—	—	WO	disclosed
US-5094950-A	Diagnostics	NIHON MEDI-PHYSICS CO., LTD. (JP)	1992-03-10	—	—	US	disclosed
US-5041373-A	Assaying cervicular fluid for elevated levels of aspartate aminotransferase	THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US)	1991-08-20	—	—	US	disclosed
WO-1991004247-A1	CHIMERIC AMINO ACIDS AND PEPTIDES CONTAINING THESE ANALOGUES	GENENTECH, INC. (US)	1991-04-04	—	—	WO	disclosed
EP-0345723-A2	Diethylenetriamine pentaacetic acid derivatives	NIHON MEDI-PHYSICS CO., LTD. (JP)	1989-12-13	—	—	EP	disclosed
US-4743535-A	Hybridization assay employing labeled probe and anti-hybrid	MILES INC. (US)	1988-05-10	—	—	US	disclosed
US-4652519-A	Bifunctional chelating agents and process for their production	YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL)	1987-03-24	—	—	US	disclosed
US-4629692-A	USING ANTI(AMADORI-REARRANGED) GLUCOSE	MILES LABORATORIES, INC. (US)	1986-12-16	—	—	US	disclosed
EP-0184710-A2	Magnetic microspheres	BAYER AG (DE)	1986-06-18	—	—	EP	disclosed
EP-0111211-B1	IMMUNOASSAY FOR NONENZYMATICALLY GLUCOSYLATED PROTEINS AND PROTEIN FRAGMENTS - AN INDEX OF GLYCEMIA	MILES LABORATORIES, INC. (US)	1986-05-21	—	—	EP	disclosed
EP-0095089-B1	IMPROVED HOMOGENEOUS BINDING ASSAY METHOD AND REAGENT SYSTEM, TEST KIT AND TEST DEVICE THEREFOR	MILES LABORATORIES, INC. (US)	1986-03-05	—	—	EP	disclosed
EP-0078952-B1	N-AMINOALKYL IODOTHYRONINE DERIVATIVES, IODOTHYRONINE IMMUNOGENS AND ANTIBODIES	MILES LABORATORIES, INC. (US)	1986-02-26	—	—	EP	disclosed
EP-0151536-A2	Method and kit for determining periodontal disease	THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US)	1985-08-14	—	—	EP	disclosed
EP-0144913-A2	Hybridization assay employing labeled probe and anti-hybrid	MILES INC. (US)	1985-06-19	—	—	EP	disclosed
US-4472301-A	REAGENT FOR IMMUNOASSAY	MILES LABORATORIES, INC. (US)	1984-09-18	—	—	US	disclosed
EP-0111211-A1	Immunoassay for nonenzymatically glucosylated proteins and protein fragments - an index of glycemia	MILES LABORATORIES, INC. (US)	1984-06-20	—	—	EP	disclosed
EP-0095639-A2	Propranolol immunogens, antibodies thereto, test device and compounds for propranolol immuno assay	MILES LABORATORIES, INC. (US)	1983-12-07	—	—	EP	disclosed
EP-0095089-A1	Improved homogeneous binding assay method and reagent system, test kit and test device therefor	MILES LABORATORIES, INC. (US)	1983-11-30	—	—	EP	disclosed
US-4404366-A	ENZYME CLEAVABLE GLYCOSIDIC LINKAGE	MILES LABORATORIES, INC. (US)	1983-09-13	—	—	US	disclosed
US-4399121-A	Iodothyronine immunogens and antibodies	MILES LABORATORIES, INC. (US)	1983-08-16	—	—	US	disclosed
EP-0078952-A1	N-aminoalkyl iodothyronine derivatives, iodothyronine immunogens and antibodies	MILES LABORATORIES, INC. (US)	1983-05-18	—	—	EP	disclosed
US-4358604-A	ANTIBODIES-USEFUL IN IMMUNOASSAY	MILES LABORATORIES, INC. (US)	1982-11-09	—	—	US	disclosed
US-4340668-A	Heme-labeled specific binding assay	MILES LABORATORIES, INC. (US)	1982-07-20	—	—	US	disclosed
US-4331590-A	β-Galactosyl-umbelliferone-labeled protein and polypeptide conjugates	MILES LABORATORIES, INC. (US)	1982-05-25	—	—	US	disclosed
US-4318982-A	FMN-Labeled specific binding assay	MILES LABORATORIES, INC. (US)	1982-03-09	—	—	US	disclosed
US-4318983-A	Fad-labeled specific binding assay monitored with apoglutathione reductase or apolipoamide dehydrogenase	MILES LABORATORIES, INC. (US)	1982-03-09	—	—	US	disclosed
US-4279992-A	Specific binding assay employing an enzyme-cleavable substrate as label	MILES LABORATORIES, INC. (US)	1981-07-21	—	—	US	disclosed
US-4255566-A	N6-(OMEGA-AMINOALKYL)ADENINE DINUCLEOTIDE DERIVATIVES; IMMUNOASSAY	MILES LABORATORIES (US)	1981-03-10	—	—	US	disclosed
US-4238565-A	Specific binding assay with a prosthetic group as a label component	MILES LABORATORIES, INC. (US)	1980-12-09	—	—	US	disclosed
US-4238565-A	Specific binding assay with a prosthetic group as a label component	MILES LABORATORIES, INC. (US)	1980-12-09	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230114250-A1	SILK-HYALURONIC ACID TISSUE FILLERS AND METHODS OF MAKING AND USING THE SAME	CD44, FN1, HDGF	GLA 11/4885KDM4E 3217/4885TP53 943/4885
US-20110052695-A1	DRUG DELIVERY PLATFORMS COMPRISING SILK FIBROIN HYDROGELS AND USES THEREOF	ILK, MSN, BPHL	GLA 2235/4885KDM4E 1081/4885TP53 3972/4885
US-20110111031-A1	Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof	ILK, MSN, BPHL	GLA 2235/4885KDM4E 1081/4885TP53 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.